H. Beeck et al., The influence of citrate concentration on the quality of plasma obtained by automated plasmapheresis: a prospective study, TRANSFUSION, 39(11-12), 1999, pp. 1266-1270
BACKGROUND: There is a need for more comprehensive work dealing with the qu
ality of plasma collected by automated plasmapheresis using different final
concentrations of citrate anticoagulant. A prospective study was performed
to examine the influence of three concentrations of sodium citrate on the
levels of clotting factors and markers of activated hemostasis and fibrinol
ysis.
STUDY DESIGN AND METHODS: Fifty-one experienced plasma donors were recruite
d for subsequent 750-mL plasmapheresis procedures using 4-percent (wt/vol)
sodium citrate. Anticoagulant-to-blood ratios of 1:16.6, 1:14.2, and 1:12.5
were used, corresponding to sodium citrate concentrations of 6 percent, 7
percent, and 8 percent (vol/vol), respectively. Between two plasmapheresis
procedures, there was a washout period of 7 days. Determinations were made
of the plasma levels of fibrinogen and factors V, VII, VIII, and IX, as wel
l as antithrombin, tissue-type plasminogen activator, and several markers o
f activated hemostasis and fibrinolysis: activated factor VII, prothrombin
splits products, D-dimers, and beta-thromboglobulin.
RESULTS: The plasma samples anticoagulated with 6-percent citrate contained
significantly higher levels of factors V, VIII, and IX than the samples an
ticoagulated with 8-percent citrate (p<0.0001, p less than or equal to 0.00
01 and p = 0.009, respectively). The citrate concentration had no influence
on the levels of fibrinogen, factor VII, antithrombin, or tissue-type plas
minogen activator. There was no evidence that the plasma samples containing
lower citrate concentrations were more prone to activation of hemostasis o
r fibrinolysis.
CONCLUSION: A reduction in the final citrate concentration of plasma collec
ted by automated plasmapheresis results in higher yields of factors V, VIII
, and IX without activation of hemostasis. More comprehensive studies shoul
d confirm previous work dealing with the establishment of the lowest citrat
e concentration acceptable in plasma used as therapeutic fresh-frozen plasm
a or as starting material for the manufacture of plasma derivatives.